SCHEMBL7293097

SCHEMBL7293097

COc1ccccc1OC1C(=O)N=C(c2ccsc2)NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK10 O94804 2/20 0.40
SLK Q9H2G2 2/20 0.40
FYN P06241 1/20 0.38
P2RX3 P56373 14/20 0.36
PDGFRB P09619 1/20 0.35
CYP2C9 P11712 2/20 0.35
CYP3A4 P08684 1/20 0.35
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34
TUBB2A Q13885 1/20 0.34
TUBB8 Q3ZCM7 1/20 0.34
TUBA3E Q6PEY2 1/20 0.34
TUBA1A Q71U36 1/20 0.34
TUBA1C Q9BQE3 1/20 0.34
TUBB6 Q9BUF5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627191 0.79 RAB9A (0.35) STK10SLKCYP3A4
SCHEMBL7297774 0.79 FYN (0.39) FYNP2RX3PDGFRBCYP2C9CYP3A4
SCHEMBL7444756 0.78 FYN (0.39) STK10SLKFYN
SCHEMBL6964330 0.76 SLK (0.42) STK10SLKCYP2C9CYP3A4MAPK1
SCHEMBL7303932 0.75 ALDH1A1 (0.40) FYNCYP3A4MAPK1
SCHEMBL13430583 0.74
SCHEMBL7303598 0.73 CA12 (0.35) CYP2C9CYP3A4
SCHEMBL7293888 0.73 CA12 (0.35)
SCHEMBL7296783 0.72 DDB1 (0.37)
SCHEMBL7330474 0.70 MAPT (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0526708-B1 Sulfonamide, preparation and use thereof as medicine and intermediate HOFFMANN LA ROCHE (CH) 2000-10-18 EP disclosed
US-5292740-A Sulfonamides HOFFMANN-LA ROCHE INC. (US) 1994-03-08 US disclosed
EP-0526708-A1 Sulfonamide, preparation and use thereof as medicine and intermediate F. HOFFMANN-LA ROCHE AG (CH) 1993-02-10 EP disclosed